Chemotherapy delivered straight to the brain: a new hope for recurrent tumors?
NCT ID NCT00308165
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a method called convection-enhanced delivery to pump the chemotherapy drug topotecan directly into brain tumors in 16 patients with recurrent malignant brain tumors. The goal was to see if this approach is safe and to find the best dose, while also monitoring tumor progression and quality of life. Because it is a phase 1 trial, the main focus is on safety, not yet on whether it works as a treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Topotecan (chemotherapy drug)
What this could lead to
If successful, this approach could offer a new way to deliver chemotherapy directly to brain tumors, potentially improving treatment effectiveness while reducing side effects.
What could go wrong
This is a very early phase 1 trial with only 16 participants, focused on safety and dosing. It is not designed to prove the treatment works, and the drug may still cause serious neurological side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAINSTEM GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University Medical Center Neurological Institute
New York, New York, 10032, United States